PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis

PKCλ/ι抑制激活ULK2介导的干扰素反应,从而抑制肿瘤发生

阅读:2
作者:Juan F Linares,Xiao Zhang,Anxo Martinez-Ordoñez,Angeles Duran,Hiroto Kinoshita,Hiroaki Kasashima,Naoko Nakanishi,Yuki Nakanishi,Ryan Carelli,Luca Cappelli,Esperanza Arias,Masakazu Yashiro,Masaichi Ohira,Sanjay Patel,Giorgio Inghirami,Massimo Loda,Ana Maria Cuervo,Maria T Diaz-Meco,Jorge Moscat

Abstract

The interferon (IFN) pathway is critical for cytotoxic T cell activation, which is central to tumor immunosurveillance and successful immunotherapy. We demonstrate here that PKCλ/ι inactivation results in the hyper-stimulation of the IFN cascade and the enhanced recruitment of CD8+ T cells that impaired the growth of intestinal tumors. PKCλ/ι directly phosphorylates and represses the activity of ULK2, promoting its degradation through an endosomal microautophagy-driven ubiquitin-dependent mechanism. Loss of PKCλ/ι results in increased levels of enzymatically active ULK2, which, by direct phosphorylation, activates TBK1 to foster the activation of the STING-mediated IFN response. PKCλ/ι inactivation also triggers autophagy, which prevents STING degradation by chaperone-mediated autophagy. Thus, PKCλ/ι is a hub regulating the IFN pathway and three autophagic mechanisms that serve to maintain its homeostatic control. Importantly, single-cell multiplex imaging and bioinformatics analysis demonstrated that low PKCλ/ι levels correlate with enhanced IFN signaling and good prognosis in colorectal cancer patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。